Prescription Medicines
Gaspren CR Tab. 15mg
- Product Category
- gastrointestinal motility regulator
- Active Ingredients
- Mosapride citrate hydrate
- Appearance
- Pink, oblong, sustained-release film-coated tablets
- Reimbursement Code
- 648104500
01 / 02
1. Ingredient content
1 tablet
- Active ingredient: Mosapride citrate hydrate (JP) ····· 15.88mg (15mg as Mosapride citrate anhydrous)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: light anhydrous silicic acid, microcrystalline cellulose, magnesium stearate, opadry pink (03F640045), corn starch, low-substituted hydroxypropyl cellulose, carnauba lead, hydroxypropyl cellulose, hypromellose
2. Effectiveness
Digestive symptoms due to functional dyspepsia (heartburn, nausea, vomiting)
3. Dosage and dosage
Adults: Mosapride citrate anhydrous, 15 mg orally once a day.
This medicine should be taken on an empty stomach, avoiding meals. (Refer to ‘3. General precautions, paragraph 2)’ among the precautions for use.)
Since this medicine is a sustained-release preparation, it should not be taken by crushing, crushing, or chewing. Swallow the tablet whole before taking it.
4. Precautions for use
1. Do not administer to the following patients.
Because this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Adverse reactions
1) Adverse reactions of Mosapride citrate sustained-release tablets
In a randomized, double-blind, active-controlled trial involving 119 patients with functional dyspepsia, 20 patients experienced adverse events. The incidence was 20.00% in the test group receiving extended-release tablets (12/60 patients; 18 events) and 13.56% in the control group receiving immediate-release tablets (8/59 patients; 11 events). No serious adverse events occurred in either group. Adverse drug reactions for which a causal relationship could not be excluded occurred in 3.33% of the test group (2/60 patients; 4 events): nausea in 1.67% (1/60 patients; 2 events), and flatulence and increased blood triglycerides, each in 1.67% (1/60 patients; 1 event). In the control group, the incidence was 6.78% (4/59 patients; 7 events): nausea in 3.39% (2/59 patients; 2 events), and abdominal discomfort, constipation, diarrhea, vomiting, and edema, each in 1.69% (1/59 patients; 1 event).
2) Adverse reactions reported in general preparations of Mosapride citrate (taken 3 times a day)
Adverse reactions occurred in 40 of 998 cases (4.0%). Major adverse reactions include diarrhea and loose stools (1.8%), dry mouth (0.5%), and malaise (0.3%).
Abnormal fluctuations were seen in clinical examination values in 30 of 792 cases (3.8%). Main contents include eosinophilia (1.1%), increased neutral fat (1.0%), and increased AST (GOT), ALT (GPT), ALP, and γ-GTP (0.4% each).
(1) Serious adverse reactions
Extreme hepatitis, liver dysfunction and jaundice (less than 0.1% each):
Severe hepatic dysfunction and jaundice accompanied by extreme hepatitis, significant elevations in AST (GOT), ALT (GPT), and γ-GTP may occur, and in some cases, death may occur. Therefore, observe thoroughly, and if abnormalities are confirmed, immediately discontinue administration and implement appropriate measures.
(2) Other adverse reactions
Hypersensitivity: rash, hives, sometimes swelling
Blood disorders: occasional eosinophilia and leukopenia
Digestive system: Abdominal bloating, oral paralysis (including tongue and lips), occasional diarrhea, loose stools, dry mouth, abdominal pain, nausea, vomiting, dysgeusia,
Liver: Occasionally elevated ALP, elevated bilirubin,
Circulatory system: Sometimes palpitations
Mental nervous system: Occasional dizziness, staggering, headache,
Others: Tremors, occasional malaise, elevation of neutral fat,
3) Domestic post-marketing surveillance results of Mosapride citrate general preparation (taken 3 times a day)
As a result of a post-marketing use results survey conducted on 745 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 1.9% (14 cases/745 cases) regardless of causal relationship, and among these, 1.3% (10 cases/745 cases) were found to have a causal relationship with this drug. Regardless of causal relationship, adverse reactions included abdominal pain, diarrhea in 4 cases, loose stools in 3 cases, nausea in 2 cases, abdominal distension, indigestion, milk overproduction, malaise, and rash in 1 case each. Among these, indigestion and milk overproduction were reported as new adverse reactions that did not appear in pre-market clinical trials.
4) As a result of analyzing domestic voluntary adverse event reporting data (1989-2013) for general preparations of Mosapride citrate (taken three times a day), the following adverse events were reported in statistically significantly higher numbers compared to adverse events occurring in other drugs for which adverse events were reported. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
● Drowsiness
5) Domestic post-marketing survey results of Mosapride citrate sustained-release tablets
5-1) As a result of a post-marketing survey conducted on 672 people for re-examination in Korea on Mosapride citric anhydride, a dosage form consisting of 10 mg sustained-release layer and 5 mg immediate-release layer, the occurrence rate of adverse events was reported to be 3.27% (22/672 people, 27 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship are listed in the table below* according to the frequency of occurrence, and there were no serious adverse drug reactions for which a causal relationship could not be ruled out. (*mark: refer to manual)
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table* according to the frequency of occurrence. (*mark: refer to manual)
5-2) As a result of a post-marketing survey conducted on 654 people for re-examination in Korea on Mosapride citric anhydride, a dosage form consisting of 11 mg of sustained-release layer and 4 mg of immediate-release layer, the occurrence rate of adverse events was reported to be 2.75% (18/654 people, 20 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship are listed in the table below* according to the frequency of occurrence, and there were no serious adverse drug reactions for which a causal relationship could not be ruled out. (*mark: refer to manual)
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table* according to the frequency of occurrence. (*mark: refer to manual)
3. General precautions
1) If no improvement in digestive tract symptoms is seen even after administration for a certain period of time (usually 2 weeks), do not administer for a long period of time.
2) Taking this drug with food may increase the blood concentration of this drug, so take it on an empty stomach (see section 9. Information for experts). The efficacy and safety of this drug when administered after a meal in patients with functional dyspepsia have not been evaluated.
4. Interaction
Because the digestive tract motility-promoting effect of this drug is related to cholinergic nerves, the effect of this drug may be reduced when administered together with anticholinergics (atropine sulfate, butylscopolamine bromide, etc.), so caution should be taken when using it together, such as leaving an interval between doses.
5. Administration to pregnant and lactating women
1) Administer to pregnant women or women who may become pregnant only when the benefits of treatment are judged to outweigh the risks. (The safety of administration during pregnancy has not been established.)
2) Avoid administration during lactation, and if unavoidable, stop breastfeeding. (Transfer to breast milk has been reported in laboratory animals.)
6. Administration to children
Safety for children, etc. has not been established (no experience in use).
7. Administration to elderly people
In general, in elderly patients, physiological functions such as renal function and liver function are reduced, so administer with caution while observing the patient's condition, and if adverse reactions occur, take appropriate measures such as reducing the dose (e.g., 7.5 mg per day as mosapride citrate anhydrous).
8. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful not to change it into another container as it may cause an accident or is undesirable in terms of maintaining quality.
9. Information for experts
A. Pharmacokinetic information
In a randomized, open-label, 3-dose, 3-sequence group crossover clinical trial targeting 38 healthy adult men, when Mosapride citrate sustained-release tablet was administered orally once a day or the regular formulation of Mosapride citrate three times a day, the geometric mean ratios of Mosapride's Cmax and AUClast to the regular formulation were 0.74 and 1.03, respectively, and were 90%. Confidence intervals are 0.63-0.85, respectively. It was observed to be 0.89-1.17.
The geometric mean ratio of Cmax and AUC of Mosapride citrate sustained-release tablets when administered orally on an empty stomach 30 minutes after a high-fat meal was 1.51 and 1.20, respectively, and Tmax increased from 1.0 hours on an empty stomach to 3.0 hours after a high-fat meal.
B. Clinical trial information
In a randomized, double-blind, active-controlled clinical trial targeting 119 patients with functional dyspepsia, once-daily administration of Mosapride citrate sustained-release tablet was non-inferior to the change in gastrointestinal symptom score at 4 weeks compared to baseline compared to administration of regular Mosapride citrate tablets three times a day.
c. Toxicity test information
In a test (104 weeks in rats, 92 weeks in mice) in which 100-300 times the usual clinical dose (30-100 mg/kg/day) was administered orally to rodents for a long period of time, an increase in the incidence of swelling (hepatocellular adenoma and thyroid follicular swelling) was observed.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 300 tablets/bottle
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredient: Mosapride citrate hydrate (JP) ····· 15.88mg (15mg as Mosapride citrate anhydrous)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: light anhydrous silicic acid, microcrystalline cellulose, magnesium stearate, opadry pink (03F640045), corn starch, low-substituted hydroxypropyl cellulose, carnauba lead, hydroxypropyl cellulose, hypromellose
2. Effectiveness
Digestive symptoms due to functional dyspepsia (heartburn, nausea, vomiting)
3. Dosage and dosage
Adults: Mosapride citrate anhydrous, 15 mg orally once a day.
This medicine should be taken on an empty stomach, avoiding meals. (Refer to ‘3. General precautions, paragraph 2)’ among the precautions for use.)
Since this medicine is a sustained-release preparation, it should not be taken by crushing, crushing, or chewing. Swallow the tablet whole before taking it.
4. Precautions for use
1. Do not administer to the following patients.
Because this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Adverse reactions
1) Adverse reactions of Mosapride citrate sustained-release tablets
In a randomized, double-blind, active-controlled trial involving 119 patients with functional dyspepsia, 20 patients experienced adverse events. The incidence was 20.00% in the test group receiving extended-release tablets (12/60 patients; 18 events) and 13.56% in the control group receiving immediate-release tablets (8/59 patients; 11 events). No serious adverse events occurred in either group. Adverse drug reactions for which a causal relationship could not be excluded occurred in 3.33% of the test group (2/60 patients; 4 events): nausea in 1.67% (1/60 patients; 2 events), and flatulence and increased blood triglycerides, each in 1.67% (1/60 patients; 1 event). In the control group, the incidence was 6.78% (4/59 patients; 7 events): nausea in 3.39% (2/59 patients; 2 events), and abdominal discomfort, constipation, diarrhea, vomiting, and edema, each in 1.69% (1/59 patients; 1 event).
2) Adverse reactions reported in general preparations of Mosapride citrate (taken 3 times a day)
Adverse reactions occurred in 40 of 998 cases (4.0%). Major adverse reactions include diarrhea and loose stools (1.8%), dry mouth (0.5%), and malaise (0.3%).
Abnormal fluctuations were seen in clinical examination values in 30 of 792 cases (3.8%). Main contents include eosinophilia (1.1%), increased neutral fat (1.0%), and increased AST (GOT), ALT (GPT), ALP, and γ-GTP (0.4% each).
(1) Serious adverse reactions
Extreme hepatitis, liver dysfunction and jaundice (less than 0.1% each):
Severe hepatic dysfunction and jaundice accompanied by extreme hepatitis, significant elevations in AST (GOT), ALT (GPT), and γ-GTP may occur, and in some cases, death may occur. Therefore, observe thoroughly, and if abnormalities are confirmed, immediately discontinue administration and implement appropriate measures.
(2) Other adverse reactions
Hypersensitivity: rash, hives, sometimes swelling
Blood disorders: occasional eosinophilia and leukopenia
Digestive system: Abdominal bloating, oral paralysis (including tongue and lips), occasional diarrhea, loose stools, dry mouth, abdominal pain, nausea, vomiting, dysgeusia,
Liver: Occasionally elevated ALP, elevated bilirubin,
Circulatory system: Sometimes palpitations
Mental nervous system: Occasional dizziness, staggering, headache,
Others: Tremors, occasional malaise, elevation of neutral fat,
3) Domestic post-marketing surveillance results of Mosapride citrate general preparation (taken 3 times a day)
As a result of a post-marketing use results survey conducted on 745 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 1.9% (14 cases/745 cases) regardless of causal relationship, and among these, 1.3% (10 cases/745 cases) were found to have a causal relationship with this drug. Regardless of causal relationship, adverse reactions included abdominal pain, diarrhea in 4 cases, loose stools in 3 cases, nausea in 2 cases, abdominal distension, indigestion, milk overproduction, malaise, and rash in 1 case each. Among these, indigestion and milk overproduction were reported as new adverse reactions that did not appear in pre-market clinical trials.
4) As a result of analyzing domestic voluntary adverse event reporting data (1989-2013) for general preparations of Mosapride citrate (taken three times a day), the following adverse events were reported in statistically significantly higher numbers compared to adverse events occurring in other drugs for which adverse events were reported. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
● Drowsiness
5) Domestic post-marketing survey results of Mosapride citrate sustained-release tablets
5-1) As a result of a post-marketing survey conducted on 672 people for re-examination in Korea on Mosapride citric anhydride, a dosage form consisting of 10 mg sustained-release layer and 5 mg immediate-release layer, the occurrence rate of adverse events was reported to be 3.27% (22/672 people, 27 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship are listed in the table below* according to the frequency of occurrence, and there were no serious adverse drug reactions for which a causal relationship could not be ruled out. (*mark: refer to manual)
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table* according to the frequency of occurrence. (*mark: refer to manual)
5-2) As a result of a post-marketing survey conducted on 654 people for re-examination in Korea on Mosapride citric anhydride, a dosage form consisting of 11 mg of sustained-release layer and 4 mg of immediate-release layer, the occurrence rate of adverse events was reported to be 2.75% (18/654 people, 20 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship are listed in the table below* according to the frequency of occurrence, and there were no serious adverse drug reactions for which a causal relationship could not be ruled out. (*mark: refer to manual)
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table* according to the frequency of occurrence. (*mark: refer to manual)
3. General precautions
1) If no improvement in digestive tract symptoms is seen even after administration for a certain period of time (usually 2 weeks), do not administer for a long period of time.
2) Taking this drug with food may increase the blood concentration of this drug, so take it on an empty stomach (see section 9. Information for experts). The efficacy and safety of this drug when administered after a meal in patients with functional dyspepsia have not been evaluated.
4. Interaction
Because the digestive tract motility-promoting effect of this drug is related to cholinergic nerves, the effect of this drug may be reduced when administered together with anticholinergics (atropine sulfate, butylscopolamine bromide, etc.), so caution should be taken when using it together, such as leaving an interval between doses.
5. Administration to pregnant and lactating women
1) Administer to pregnant women or women who may become pregnant only when the benefits of treatment are judged to outweigh the risks. (The safety of administration during pregnancy has not been established.)
2) Avoid administration during lactation, and if unavoidable, stop breastfeeding. (Transfer to breast milk has been reported in laboratory animals.)
6. Administration to children
Safety for children, etc. has not been established (no experience in use).
7. Administration to elderly people
In general, in elderly patients, physiological functions such as renal function and liver function are reduced, so administer with caution while observing the patient's condition, and if adverse reactions occur, take appropriate measures such as reducing the dose (e.g., 7.5 mg per day as mosapride citrate anhydrous).
8. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful not to change it into another container as it may cause an accident or is undesirable in terms of maintaining quality.
9. Information for experts
A. Pharmacokinetic information
In a randomized, open-label, 3-dose, 3-sequence group crossover clinical trial targeting 38 healthy adult men, when Mosapride citrate sustained-release tablet was administered orally once a day or the regular formulation of Mosapride citrate three times a day, the geometric mean ratios of Mosapride's Cmax and AUClast to the regular formulation were 0.74 and 1.03, respectively, and were 90%. Confidence intervals are 0.63-0.85, respectively. It was observed to be 0.89-1.17.
The geometric mean ratio of Cmax and AUC of Mosapride citrate sustained-release tablets when administered orally on an empty stomach 30 minutes after a high-fat meal was 1.51 and 1.20, respectively, and Tmax increased from 1.0 hours on an empty stomach to 3.0 hours after a high-fat meal.
B. Clinical trial information
In a randomized, double-blind, active-controlled clinical trial targeting 119 patients with functional dyspepsia, once-daily administration of Mosapride citrate sustained-release tablet was non-inferior to the change in gastrointestinal symptom score at 4 weeks compared to baseline compared to administration of regular Mosapride citrate tablets three times a day.
c. Toxicity test information
In a test (104 weeks in rats, 92 weeks in mice) in which 100-300 times the usual clinical dose (30-100 mg/kg/day) was administered orally to rodents for a long period of time, an increase in the incidence of swelling (hepatocellular adenoma and thyroid follicular swelling) was observed.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 300 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | Gaspren CR Tab. 15mg | Precautions for use | 2021.08.10 | Change plan_Precautions for use_Gaspresso tablets (including change comparison table).pdfFile under review |